Abstract
Thymosin β4 – an endogenously occurring 43 amino acid peptide – has recently been shown to possess cardioprotective properties in the setting of acute myocardial infarction. This review focuses on the reported mechanisms of action through which Thymosin β4 might accomplish this effect and the clinical prospects for its use as a therapeutic agent.
Similar content being viewed by others
References
Safer D, Golla R, Nachmias VT (1990) Isolation of a 5-kilodalton actin-sequestering peptide from human blood platelets. Proc Natl Acad Sci USA 87:2536–2540
Safer D, Elzinga M, Nachmias VT (1991) Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem 266:4029–4032
Huff T, Muller CS, Otto AM, Netzker R, Hannappel E (2001) beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 33:205–220
Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D (2004) Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432:466–472
Tu Y, Li F, Goicoechea S, Wu C (1999) The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol Cell Biol 19:2425–2434
Fukuda T, Chen K, Shi X, Wu C (2003) PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J Biol Chem 278:51324–51333
Brazil DP, Park J, Hemmings BA (2002) PKB binding proteins. Getting in on the Akt. Cell 111:293–303
Woodgett JR (2005) Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17:150–157
Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S (2003) Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 278:22374–22378
Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR (2007) Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445:177–182
Bhaskar PT, Hay N (2007) The two TORCs and akt. Dev Cell 12:487–502
Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S. Molkentin JD, Zou Y, Komuro I (2007) p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446:444–448
Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115:2108–2118
Conlon JM, Grimelius L, Wallin G, Thim L (1988) Isolation and structural characterization of thymosin-beta 4 from a human medullary thyroid carcinoma. J Endocrinol 118:155–159
Hall AK (1991) Differential expression of thymosin genes in human tumors and in the developing human kidney. Int J Cancer 48:672–677
Yamamoto T, Gotoh M, Kitajima M, Hirohashi S (1993) Thymosin beta-4 expression is correlated with metastatic capacity of colorectal carcinomas. Biochem Biophys Res Commun 193:706–710
Chen C, Li M, Yang H, Chai H, Fisher W, Yao Q (2005) Roles of thymosins in cancers and other organ systems. World J Surg 29:264–270
Cha HJ, Jeong MJ, Kleinman HK (2003) Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 95:1674–1680
Larsson LI, Holck S (2007) Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment. Hum Pathol 38:114–119
Grant DS, Kinsella JL, Kibbey MC, LaFlamme S, Burbelo PD, Goldstein A L, Kleinman HK (1995) Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. J Cell Sci 108(Pt 12):3685–3694
Malinda KM, Goldstein AL, Kleinman HK (1997) Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J 11:474–481
Koutrafouri V, Leondiadis L, Avgoustakis K, Livaniou E, Czarnecki J, Ithakissios DS, Evangelatos GP (2001) Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim Biophys Acta 1568:60–66
Frangogiannis NG (2006) Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 13:1877–1893
Tillmanns J, Carlsen H, Blomhoff R, Valen G, Calvillo L, Ertl G, Bauersachs J, Frantz S (2006) Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction. Biochem Biophys Res Commun 342:773–774
Hall G, Hasday JD, Rogers TB (2006) Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 41:580–591
Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109:S81–S96 (Suppl)
Sosne G, Qiu P, Christopherson PL, Wheater MK (2007) Thymosin beta 4 suppression of corneal NFkappaB: A potential anti-inflammatory pathway. Exp Eye Res 84:663–669
Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T (1997) In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 3:894–899
Cavasin MA, Rhaleb NE, Yang XP, Carretero OA (2004) Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 43:1140–1145
Wang D, Carretero OA, Yang XY, Rhaleb NE, Liu YH, Liao TD, Yang XP (2004) N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol 287:H2099–H2105
Liu JM, Lawrence F, Kovacevic M, Bignon J, Papadimitriou E, Lallemand JY, Katsoris P, Potier P, Fromes Y, Wdzieczak-Bakala J (2003) The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 101:3014–3020
Waeckel L, Bignon J, Liu JM, Markovits D, Ebrahimian TG, Vilar J, Mees B, Blanc-Brude O, Barateau V, Le Ricousse-Roussanne S, Duriez M, Tobelem G, Wdzieczak-Bakala J, Levy BI, Silvestre JS (2006) Tetrapeptide AcSDKP induces postischemic neovascularization through monocyte chemoattractant protein-1 signaling. Arterioscler Thromb Vasc Biol 26:773–779
Yang F, Yang XP, Liu YH, Xu J, Cingolani O, Rhaleb, NE., Carretero OA (2004) Ac-SDKP reversesss inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 43:229–236
Huff T, Otto AM, Muller CS, Meier M, Hannappel E (2002) Thymosin beta4 is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen. FASEB J 16:691–696
Mora CA, Baumann CA, Paino JE, Goldstein AL, Badamchian M (1997) Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice. Int J Immunopharmacol 19:1–8
Naito AT, Tominaga A, Oyamada M, Oyamada Y, Shiraishi I, Monzen K, Komuro I, Takamatsu T (2003) Early stage-specific inhibitions of cardiomyocyte differentiation and expression of Csx/Nkx-2.5 and GATA-4 by phosphatidylinositol 3-kinase inhibitor LY294002. Exp Cell Res 291:56–69
McDevitt TC, Laflamme MA, Murry CE (2005) Proliferation of cardiomyocytes derived from human embryonic stem cells is mediated via the IGF/PI 3-kinase/Akt signaling pathway. J Mol Cell Cardiol 39:865–873
Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr (2002) Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99:12333–12338
Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, Liao R Rosenzweig A (2002) Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277:22896–22901
Shiojima I, Walsh K (2006) Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 20:3347–3365
Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K (2000) Akt promotes survival of cardiomyocytes in vitro and protects against ischemia–reperfusion injury in mouse heart. Circulation 101:660–667
Hausenloy DJ, Yellon DM (2006) Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70:240–253
Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ, Stevenson RD (1999) Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 5:1424–1427
Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD (2002) Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res 74:293–299
Badamchian M, Fagarasan MO, Danner RL, Suffredini AF, Damavandy H, Goldstein AL (2003) Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. Int Immunopharmacol 3:1225–1233
Leeanansaksiri W, DeSimone SK, Huff T, Hannappel E, Huff TF (2004) Thymosin beta 4 and its N-terminal tetrapeptide, AcSDKP, inhibit proliferation, and induce dysplastic, non-apoptotic nuclei and degranulation of mast cells. Chem Biodivers 1:1091–1100
Wyczolkowska J, Walczak-Drzewiecka A, Wagner W, Dastych J (2007) Thymosin beta4 and thymosin beta4-derived peptides induce mast cell exocytosis. Peptides 28:752–759
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rossdeutsch, A., Smart, N. & Riley, P.R. Thymosin β4 and Ac-SDKP: Tools to mend a broken heart. J Mol Med 86, 29–35 (2008). https://doi.org/10.1007/s00109-007-0243-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-007-0243-9